BIOVF
Swedish Orphan Biovitrum AB (publ)
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Last price
47.35
▼ 0.81 (1.68%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
48.16
Day high
47.35
Day low
47.35
Volume
200
Market cap
$16.51B
P/E (TTM)
115.49
52W range
29.18 – 49.03
Trailing performance
Returnvs SPY
1W
-0.09%
+1.1%
1M
-1.77%
-5.1%
3M
+1.44%
-0.9%
6M
+30.16%
+18.3%
YTD
+36.62%
+24.7%
1Y
+66.24%
+46.1%
3Y
+161.74%
+86.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BIOVF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
34.92M
Total on file
Fundamentals
Market cap$16.51B
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA$12.41B
Net income—
EPS (TTM)$0.41
Free cash flow$3.42B
Total cash—
Total debt—
Book value / share$104.39
Shares outstanding347.29M
Float223.20M
Short % of float—
Dividend yield—
Beta (5Y)0.28
Valuation & profitability ratios
Trailing P/E115.49
Forward P/E—
PEG ratio0.32
Price / sales—
Price / book0.45
EV / revenue—
EV / EBITDA—
Gross margin78.49%
Operating margin0.00%
Profit margin4.51%
Return on equity3.40%
Return on assets7.71%
Debt / equity41.61
Current ratio0.88
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $28.24B | $26.03B | $22.12B | $18.79B | +8.5% |
| Operating revenue | $28.24B | $26.03B | $22.12B | $18.79B | +8.5% |
| Cost of revenue | $6.25B | $5.79B | $5.00B | $4.78B | +8.1% |
| Gross profit | $21.99B | $20.24B | $17.13B | $14.01B | +8.6% |
| Research & development | $3.32B | $3.54B | $2.80B | $2.35B | -6.2% |
| Selling, general & admin | $14.29B | $7.42B | $7.07B | $7.85B | +92.6% |
| Total operating expense | $21.06B | $14.63B | $12.95B | $10.17B | +44.0% |
| Operating income | $922.00M | $5.62B | $4.18B | $3.85B | -83.6% |
| Net interest income | -$807.00M | -$1.27B | -$1.14B | -$481.00M | +36.3% |
| Pre-tax income | $34.00M | $4.41B | $2.95B | $3.32B | -99.2% |
| Tax provision | -$442.00M | $528.00M | $546.00M | $683.00M | -183.7% |
| Net income | $478.00M | $3.88B | $2.41B | $2.64B | -87.7% |
| Net income to common | $478.00M | $3.88B | $2.41B | $2.64B | -87.7% |
| Basic EPS | 1.39 | 11.37 | 7.47 | 8.52 | -87.8% |
| Diluted EPS | 1.37 | 11.24 | 7.39 | 8.44 | -87.8% |
| EBIT | $836.00M | $5.65B | $4.07B | $3.78B | -85.2% |
| EBITDA | $10.93B | $9.32B | $7.26B | $6.05B | +17.2% |
| Basic shares | 344.30M | 341.73M | 322.66M | 309.48M | +0.8% |
| Diluted shares | 347.61M | 345.56M | 325.97M | 312.46M | +0.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.04B | $1.14B | $904.00M | $1.36B | -8.7% |
| Cash & short-term investments | $1.04B | $1.14B | $904.00M | $1.36B | -8.7% |
| Accounts receivable | $5.86B | $5.20B | $5.17B | $5.25B | +12.7% |
| Inventory | $5.13B | $4.16B | $3.87B | $3.33B | +23.3% |
| Total current assets | $14.53B | $13.16B | $12.16B | $11.21B | +10.4% |
| Property, plant & equipment | $1.63B | $1.58B | $1.30B | $274.00M | +3.0% |
| Goodwill & intangibles | $49.08B | $58.97B | $59.58B | $40.01B | -16.8% |
| Total assets | $67.43B | $75.44B | $74.03B | $52.50B | -10.6% |
| Total current liabilities | $16.07B | $12.60B | $19.09B | $14.86B | +27.5% |
| Current debt | $5.94B | $3.93B | $8.81B | $5.80B | +51.3% |
| Long-term debt | $5.18B | $12.41B | $11.36B | $2.97B | -58.2% |
| Total debt | $11.49B | $16.73B | $20.49B | $9.10B | -31.3% |
| Total liabilities | $29.71B | $35.15B | $40.16B | $25.97B | -15.5% |
| Retained earnings | $22.40B | $21.92B | $18.05B | $15.79B | +2.2% |
| Shareholder equity | $37.72B | $40.29B | $33.87B | $26.52B | -6.4% |
| Working capital | -$1.54B | $562.00M | -$6.93B | -$3.65B | -374.2% |
| Net tangible assets | -$11.36B | -$18.68B | -$25.71B | -$13.49B | +39.2% |
| Shares issued | 357.41M | 356.00M | 354.36M | 324.34M | +0.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $34.00M | $4.41B | $2.95B | $3.32B | -99.2% |
| Depreciation & amortisation | $10.10B | $3.68B | $3.20B | $2.27B | +174.4% |
| Stock-based compensation | $250.00M | $218.00M | — | — | +14.7% |
| Change in working capital | -$507.00M | -$180.00M | -$1.16B | -$806.00M | -181.7% |
| Operating cash flow | $8.56B | $7.39B | $4.47B | $4.58B | +15.9% |
| Capital expenditure | -$3.15B | -$3.00B | -$4.94B | -$1.48B | -4.9% |
| Investing cash flow | -$4.29B | -$3.09B | -$21.90B | -$1.48B | -38.9% |
| Financing cash flow | -$4.32B | -$4.00B | $17.01B | -$2.90B | -8.0% |
| Free cash flow | $5.41B | $4.38B | -$473.00M | $3.10B | +23.5% |
| End cash position | $1.04B | $1.14B | $904.00M | $1.36B | -8.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $7.84B | $7.18B | $7.82B | $6.17B | $6.46B | +9.2% |
| Operating revenue | $7.84B | $7.18B | $7.82B | $6.17B | $6.46B | +9.2% |
| Cost of revenue | $1.83B | $1.75B | $1.62B | $1.43B | $1.59B | +4.7% |
| Gross profit | $6.01B | $5.44B | $6.20B | $4.75B | $4.88B | +10.6% |
| Research & development | $1.14B | $948.00M | $879.00M | $851.00M | $834.00M | +20.6% |
| Selling, general & admin | $1.68B | $1.88B | $2.96B | $1.88B | $1.78B | -10.7% |
| Total operating expense | $3.94B | $3.57B | $3.84B | $3.60B | $3.52B | +10.4% |
| Operating income | $2.07B | $1.87B | $2.36B | $1.15B | $1.36B | +10.9% |
| Net interest income | -$204.00M | -$173.00M | -$185.00M | -$216.00M | -$262.00M | -17.9% |
| Pre-tax income | $1.41B | $1.68B | $2.17B | $794.00M | $1.10B | -15.9% |
| Tax provision | $315.00M | $363.00M | $309.00M | $160.00M | $221.00M | -13.2% |
| Net income | $1.10B | $1.32B | $1.86B | $636.00M | $875.00M | -16.8% |
| Net income to common | $1.10B | $1.32B | $1.86B | $636.00M | $875.00M | -16.8% |
| Basic EPS | 3.17 | 3.81 | 5.39 | 1.85 | 2.55 | -16.8% |
| Diluted EPS | 3.14 | 3.77 | 5.34 | 1.83 | 2.52 | -16.7% |
| EBIT | $2.07B | $1.87B | $2.36B | $1.15B | $1.36B | +10.9% |
| EBITDA | $3.33B | $2.65B | $3.11B | $2.04B | $2.30B | +25.6% |
| Basic shares | 346.18M | 345.76M | 345.34M | 343.73M | 343.45M | +0.1% |
| Diluted shares | 350.06M | 349.36M | 348.65M | 347.17M | 346.97M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.08B | $940.00M | $1.04B | $1.06B | $997.00M | +15.1% |
| Cash & short-term investments | $1.08B | $940.00M | $1.04B | $1.06B | $997.00M | +15.1% |
| Accounts receivable | $7.46B | $6.70B | $5.86B | $5.41B | $5.13B | +11.4% |
| Inventory | $6.45B | $5.08B | $5.13B | $4.26B | $3.88B | +27.0% |
| Total current assets | $17.42B | $15.30B | $14.53B | $12.30B | $11.71B | +13.9% |
| Property, plant & equipment | $1.63B | $1.63B | $1.63B | $1.64B | $1.58B | -0.4% |
| Goodwill & intangibles | $61.30B | $61.85B | $49.08B | $53.49B | $55.36B | -0.9% |
| Total assets | $82.89B | $81.26B | $67.43B | $68.75B | $70.12B | +2.0% |
| Total current liabilities | $19.91B | $21.70B | $16.07B | $12.27B | $11.96B | -8.3% |
| Current debt | $8.72B | $11.03B | $5.94B | $3.92B | $3.91B | -20.9% |
| Long-term debt | $8.48B | $7.65B | $5.18B | $8.53B | $9.75B | +10.8% |
| Total debt | $17.59B | $19.06B | $11.49B | $12.81B | $14.02B | -7.7% |
| Total liabilities | $40.62B | $40.87B | $29.71B | $29.68B | $31.08B | -0.6% |
| Retained earnings | $24.82B | $23.72B | $22.40B | $23.43B | $22.80B | +4.6% |
| Shareholder equity | $42.26B | $40.38B | $37.72B | $39.06B | $39.03B | +4.7% |
| Working capital | -$2.49B | -$6.41B | -$1.54B | $27.00M | -$246.00M | +61.2% |
| Net tangible assets | -$19.04B | -$21.47B | -$11.36B | -$14.43B | -$16.33B | +11.3% |
| Shares issued | 357.41M | 357.41M | 357.41M | 356.00M | 356.00M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $1.41B | $1.68B | $2.17B | $794.00M | $1.10B | — | -15.9% |
| Depreciation & amortisation | $1.26B | $782.00M | $754.00M | $889.00M | $938.00M | — | +60.6% |
| Stock-based compensation | — | $72.00M | $67.00M | $57.00M | $67.00M | $65.00M | — |
| Change in working capital | -$274.00M | -$673.00M | $231.00M | -$190.00M | $1.02B | — | +59.3% |
| Operating cash flow | $1.91B | $1.13B | $2.98B | $1.45B | $2.29B | — | +69.8% |
| Capital expenditure | -$340.00M | -$254.00M | -$36.00M | -$421.00M | -$11.00M | — | -33.9% |
| Investing cash flow | -$378.00M | -$8.75B | -$1.08B | -$424.00M | -$94.00M | — | +95.7% |
| Financing cash flow | -$1.42B | $7.50B | -$1.90B | -$988.00M | -$2.29B | — | -118.9% |
| Free cash flow | $1.57B | $872.00M | $2.94B | $1.03B | $2.28B | — | +80.3% |
| End cash position | $1.08B | $940.00M | $1.04B | $1.06B | $997.00M | — | +15.1% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $9.05B | +16.4% |
| Next quarter | — | — | $9.07B | +16.0% |
| Current year | — | — | $33.11B | +17.3% |
| Next year | — | — | $37.14B | +12.2% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders10.05%
Held by institutions75.15%
Institutions holding321
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
48.20
-1.76% from price
SMA 20
48.24
-0.17% from price
SMA 50
48.34
-0.38% from price
SMA 100
46.39
+2.07% from price
SMA 200
41.68
+15.54% from price
EMA 12
48.22
-1.81% from price
EMA 26
48.28
-1.92% from price
EMA 50
47.91
-1.17% from price
RSI (14)
34.4
Neutral
MACD (12,26,9)
-0.06
Hist -0.02
ATR (14)
0.02
0.03% of price
Realised vol 30D
4.8%
Annualised
Bollinger upper
48.60
20, 2σ
Bollinger lower
47.88
20, 2σ
50 / 200 cross
Golden
48.34 vs 41.68
Trend bias
Above 200
+15.54%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.13
Less volatile than market
Correlation to SPY
-0.07
Largely independent
Realised vol 30D
4.8%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-5.1%
Peak to trough
Max drawdown 5Y
-36.8%
Peak to trough
ATR 14
0.02
0.03% of price
Beta (reported)
0.28
5Y monthly, from filing
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 24, 21 | Barclays | DOWNGRADE | Overweight | Equal-Weight |
Headlines
Swedish Orphan Biovitrum (OM:SOBI) Following Its Lacutamab Deal And The Undervalued Narrative
Simply Wall St. · 10d ago
Swedish Orphan Biovitrum (OM:SOBI) Stock Looks Strong On Returns But Fully Priced On Earnings
Simply Wall St. · 10d ago
Sobi licenses Innate’s CTCL drug for up to $580m as it heads to Phase III
Pharmaceutical Technology · 14d ago
Innate Pharma, Sobi Partner on Late-Stage Study for Lacutamab
MT Newswires · 15d ago
Innate Pharma, Swedish Orphan Biovitrum Partner to Advance Phase 3 Lymphoma Drug; Shares Surge Pre-Bell
MT Newswires · 15d ago
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
PR Newswire · 15d ago
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
Business Wire · 15d ago
BioNTech Names Guido Oelkers as Chief Executive
MT Newswires · 22d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.